Overview

QTX3046 in Patients With KRAS G12D Mutations

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.
Phase:
PHASE1
Details
Lead Sponsor:
Quanta Therapeutics
Treatments:
Cetuximab